Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1995 Feb;39(2):507–512. doi: 10.1128/aac.39.2.507

Effect of aerobic and anaerobic environments on antistaphylococcal activities of five fluoroquinolones.

R A Zabinski 1, K J Walker 1, A J Larsson 1, J A Moody 1, G W Kaatz 1, J C Rotschafer 1
PMCID: PMC162568  PMID: 7726522

Abstract

A previously established in vitro pharmacodynamic system was used to evaluate the antistaphylococcal activities of five fluoroquinolones under both aerobic and anaerobic conditions. Staphylococcus aureus ATCC 29213 was exposed to a 5-micrograms/ml concentration of each of the following fluoroquinolones: ciprofloxacin, ofloxacin, temafloxacin, sparfloxacin, and clinafloxacin. Terminal elimination half-lives of 4, 6, 8, 8, and 13 h were simulated for the respective drugs. Each fluoroquinolone was bactericidal under both aerobic and anaerobic conditions. However, the bactericidal activity of each fluoroquinolone was delayed by anaerobiosis. This difference in fluoroquinolone activity under aerobic and anaerobic conditions could not be attributed to any particular parameter or physiochemical property but was most likely caused by a combination of factors (e.g., variations in hydrophobicity, intracellular pH, antibiotic concentration, and structure-activity relationships). Fluoroquinolone uptake studies were also performed to investigate the possibility of active, energy-dependent transport mechanisms in S. aureus ATCC 29213. Uptake studies indicated that active efflux does occur in S. aureus ATCC 29213.

Full Text

The Full Text of this article is available as a PDF (240.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bernard H., Tancrede C., Livrelli V., Morand A., Barthelemy M., Labia R. A novel plasmid-mediated extended-spectrum beta-lactamase not derived from TEM- or SHV-type enzymes. J Antimicrob Chemother. 1992 May;29(5):590–592. doi: 10.1093/jac/29.5.590. [DOI] [PubMed] [Google Scholar]
  2. Chapman J. S., Georgopapadakou N. H. Routes of quinolone permeation in Escherichia coli. Antimicrob Agents Chemother. 1988 Apr;32(4):438–442. doi: 10.1128/aac.32.4.438. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Cooper M. A., Andrews J. M., Wise R. Bactericidal activity of sparfloxacin and ciprofloxacin under anaerobic conditions. J Antimicrob Chemother. 1991 Sep;28(3):399–405. doi: 10.1093/jac/28.3.399. [DOI] [PubMed] [Google Scholar]
  4. Crumplin G. C., Smith J. T. Nalidixic acid: an antibacterial paradox. Antimicrob Agents Chemother. 1975 Sep;8(3):251–261. doi: 10.1128/aac.8.3.251. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Fernandes P. B., Hanson C. W., Stamm J. M., Vojtko C., Shipkowitz N. L., St Martin E. The frequency of in-vitro resistance development to fluoroquinolones and the use of a murine pyelonephritis model to demonstrate selection of resistance in vivo. J Antimicrob Chemother. 1987 Apr;19(4):449–465. doi: 10.1093/jac/19.4.449. [DOI] [PubMed] [Google Scholar]
  6. Furet Y. X., Deshusses J., Pechère J. C. Transport of pefloxacin across the bacterial cytoplasmic membrane in quinolone-susceptible Staphylococcus aureus. Antimicrob Agents Chemother. 1992 Nov;36(11):2506–2511. doi: 10.1128/aac.36.11.2506. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Garrison M. W., Vance-Bryan K., Larson T. A., Toscano J. P., Rotschafer J. C. Assessment of effects of protein binding on daptomycin and vancomycin killing of Staphylococcus aureus by using an in vitro pharmacodynamic model. Antimicrob Agents Chemother. 1990 Oct;34(10):1925–1931. doi: 10.1128/aac.34.10.1925. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Hirai K., Aoyama H., Irikura T., Iyobe S., Mitsuhashi S. Differences in susceptibility to quinolones of outer membrane mutants of Salmonella typhimurium and Escherichia coli. Antimicrob Agents Chemother. 1986 Mar;29(3):535–538. doi: 10.1128/aac.29.3.535. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Kaatz G. W., Seo S. M., Ruble C. A. Efflux-mediated fluoroquinolone resistance in Staphylococcus aureus. Antimicrob Agents Chemother. 1993 May;37(5):1086–1094. doi: 10.1128/aac.37.5.1086. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Kaatz G. W., Seo S. M., Ruble C. A. Mechanisms of fluoroquinolone resistance in Staphylococcus aureus. J Infect Dis. 1991 May;163(5):1080–1086. doi: 10.1093/infdis/163.5.1080. [DOI] [PubMed] [Google Scholar]
  11. Kayser F. H., Novak J. In vitro activity of ciprofloxacin against gram-positive bacteria. An overview. Am J Med. 1987 Apr 27;82(4A):33–39. [PubMed] [Google Scholar]
  12. Lewin C. S., Morrissey I., Smith J. T. The mode of action of quinolones: the paradox in activity of low and high concentrations and activity in the anaerobic environment. Eur J Clin Microbiol Infect Dis. 1991 Apr;10(4):240–248. doi: 10.1007/BF01966996. [DOI] [PubMed] [Google Scholar]
  13. Mitsuyama J., Itoh Y., Takahata M., Okamoto S., Yasuda T. In vitro antibacterial activities of tosufloxacin against and uptake of tosufloxacin by outer membrane mutants of Escherichia coli, Proteus mirabilis, and Salmonella typhimurium. Antimicrob Agents Chemother. 1992 Sep;36(9):2030–2036. doi: 10.1128/aac.36.9.2030. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Morrissey I., Smith J. T. Absence of bactericidal activity of sparfloxacin and ciprofloxacin under anaerobic conditions. J Antimicrob Chemother. 1992 May;29(5):589–590. doi: 10.1093/jac/29.5.589. [DOI] [PubMed] [Google Scholar]
  15. Nakanishi N., Yoshida S., Wakebe H., Inoue M., Yamaguchi T., Mitsuhashi S. Mechanisms of clinical resistance to fluoroquinolones in Staphylococcus aureus. Antimicrob Agents Chemother. 1991 Dec;35(12):2562–2567. doi: 10.1128/aac.35.12.2562. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Shen L. L., Mitscher L. A., Sharma P. N., O'Donnell T. J., Chu D. W., Cooper C. S., Rosen T., Pernet A. G. Mechanism of inhibition of DNA gyrase by quinolone antibacterials: a cooperative drug--DNA binding model. Biochemistry. 1989 May 2;28(9):3886–3894. doi: 10.1021/bi00435a039. [DOI] [PubMed] [Google Scholar]
  17. Wolfson J. S., Hooper D. C. Fluoroquinolone antimicrobial agents. Clin Microbiol Rev. 1989 Oct;2(4):378–424. doi: 10.1128/cmr.2.4.378. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Zabinski R. A., Larsson A. J., Walker K. J., Gilliland S. S., Rotschafer J. C. Elimination of quinolone antibiotic carryover through use of antibiotic-removal beads. Antimicrob Agents Chemother. 1993 Jun;37(6):1377–1379. doi: 10.1128/aac.37.6.1377. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Zabinski R. A., Vance-Bryan K., Krinke A. J., Walker K. J., Moody J. A., Rotschafer J. C. Evaluation of activity of temafloxacin against Bacteroides fragilis by an in vitro pharmacodynamic system. Antimicrob Agents Chemother. 1993 Nov;37(11):2454–2458. doi: 10.1128/aac.37.11.2454. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES